Emboline expects that its technology designed to reduce stroke risk during structural heart procedures will launch in the US ...
Q4 2025 Earnings Call March 18, 2026 4:30 PM EDTCompany ParticipantsMaria Sainz - CEO, President & DirectorBrett Hale - ...
Overall, we have raised a total of $472.2 million in net proceeds from the sale of 12 container vessels since December 2023, and have recycled this capital into our focus on gas transportation assets.
MedPage Today on MSN
The Chase Is Still On in Heart Pump Innovation
New concepts in device therapy for advanced heart failure presented in early reports ...
TD Cowen 46th Annual Health Care Conference March 2, 2026 9:50 AM ESTCompany ParticipantsScott Ullem - Corporate ...
Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular disease (CVD) worldwide, today announced that additional REDUCE-IT patient subgroup analysis and ...
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q4 2025 Earnings Call Transcript March 5, 2026 Lexicon Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-0.04, expectations were $-0.07.
Lead candidate, EDIT-401, which demonstrated >90% mean LDL-C reduction in preclinical studies, remains on track for IND/CTA submission by mid-2026 Preparing to initiate Company's first-in-human clinic ...
FY25 Total Revenue Grew 21% Y/Y to $403.1 Million; FY25 U.S. Net Product Revenue Grew 38% Y/Y to $159.6 Million –– Q4 2025 U.S. Net Product ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results